[Therapy of a patient with graft versus host reaction following allogenic bone marrow transplantation with the monoclonal antibody OKT3 (Orthoclone OKT3)].
Jung
G
G
Medizinische Klinik III, Universität München, Klinikum Grosshadern.
Holler
E
E
Kolb
H J
HJ
Wilmanns
W
W
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D006086:Graft vs Host Disease / Q000628:therapy*; D006801:Humans; D007165:Immunosuppression Therapy; D015479:Leukemia, Myelomonocytic, Acute / Q000628:therapy*; D008297:Male; D016853:Muromonab-CD3; D012074:Remission Induction
D000911:Antibodies, Monoclonal; D016853:Muromonab-CD3
Therapie eines Patienten mit Graft-versus-Host-Reaktion nach allogener Knochenmarktransplantation mit dem monoklonalen Antikörper OKT3 (Orthoclone OKT3).